Health Care ETFs Compared: XLV vs. FHLC Holdings and Performance
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of the Health Care Select Sector SPDR ETF (XLV) and the Fidelity MSCI Health Care Index ETF (FHLC) was released. XLV tracks the S&P 500 health care companies and holds $43.62 billion in assets. FHLC tracks the MSCI USA IMI Health Care Index and holds $3.60 billion.
From aol.com
Why it matters
XLV includes 65 positions, while FHLC includes 337, giving FHLC broader exposure to small and mid-size companies. Eli Lilly and Johnson & Johnson account for 27% of XLV but only 22% of FHLC. Over five years, XLV outperformed FHLC, achieving a 49% return compared to 42% for FHLC.
From aol.com
Who's involved
- Eli Lilly and CompanyMajor holding in both XLV and FHLC
- Johnson & JohnsonMajor holding in both XLV and FHLC
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
-
Eli Lilly and Company
American pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- CRISPR Therapeutics announced that A.J. Silver will succeed Raju Prasad as CFO, following Silver's time at Ernst & Young LLP.